Evidence map›Paper›PMID 27515662›Full record

ArticleParasites & vectors2016

Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits classical and alternative complement pathways.

Naylene C S Silva, Vladimir F Vale, Paula F Franco, Nelder F Gontijo, Jesus G Valenzuela, Marcos H Pereira, Mauricio R V Sant'Anna, Daniel S Rodrigues, Walter S Lima, Blima Fux and 1 more

Abstract read
In one paragraph

Article in Parasites & vectors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Metazoan Parasite Vaccines: Present Status and Future Prospects.Frontiers in cellular and infection microbiology · 2018
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Naylene C S SilvaDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Vladimir F ValeDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Paula F FrancoDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Nelder F GontijoDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Jesus G ValenzuelaVector Molecular Biology Section, LMVR, National Institute of Allergy and Infectious Diseases, NIH, Rockville, MD, USA.
Marcos H PereiraDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Mauricio R V Sant'AnnaDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Daniel S RodriguesEmpresa de Pesquisa Agropecuária de Minas Gerais, Fazenda Experimental Santa Rita, Rodovia MG 424 km 64, Caixa Postal 295, Prudente de Morais, 35701-970, MG, Brazil.
Walter S LimaDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Blima FuxDepartamento de Patologia, Universidade Federal do Espírito Santo, Vitória, MG, Brazil.
Ricardo N AraujoDepartamento de Parasitologia, Laboratório de Fisiologia de Insetos Hematófagos, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil. rnaraujo@icb.ufmg.br.

Funding

Molecular approaches to understand vector-host and vector-pathogen interactionsZIAAI000932 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VALENZUELA, JESUS · 2009 to 2025
$23.1M
6 · The paper itself

Abstract

backgroundRhipicephalus (Boophilus) microplus is the main ectoparasite affecting livestock worldwide. For a successful parasitism, ticks need to evade several immune responses of their hosts, including the activation of the complement system. In spite of the importance of R. microplus, previous work only identified one salivary molecule that blocks the complement system. The current study describes complement inhibitory activities induced by R. microplus salivary components and mechanisms elicited by putative salivary proteins on both classical and alternative complement pathways.

resultsWe found that R. microplus saliva from fully- and partially engorged females was able to inhibit both pathways. Saliva acts strongly at the initial steps of both complement activation pathways. In the classical pathway, the saliva blocked C4 cleavage, and hence, deposition of C4b on the activation surface, suggesting that the inhibition occurs at some point between C1q and C4. In the alternative pathway, saliva acts by binding to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and reducing C3b production and deposition as well as cleavage of factor B. Saliva has no effect on formation or decay of the C6 to C8 components of the membrane attack complex.

conclusionThe saliva of R. microplus is able to inhibit the early steps of classical and alternative pathways of the complement system. Saliva acts by blocking C4 cleavage and deposition of C4b on the classical pathway activation surface and, in the alternative pathway, saliva bind to initial components of the cascade (C3b and properdin) thereby preventing the C3 convertase formation and the production and deposition of additional C3b.

Indexed as

AnimalsComplement Inactivator ProteinsComplement Pathway, AlternativeComplement Pathway, ClassicalImmune EvasionImmune ToleranceRhipicephalusSalivaComplement Inactivator ProteinsAlternative pathwayClassical pathwayComplement inhibitionRhipicephalus (Boophilus) microplusSaliva

Identifiers

PMID27515662
PMCPMC4982215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.